8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 27, 2026·SEC
Instil Bio, Inc.(TIL)Earnings, Financials & Key Ratios
TIL•NASDAQ
Price updated Jun 13, 2026
AboutInstil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.Show more
- Revenue$0
- EBITDA-$52M+25.1%
- Net Income-$71M+3.7%
- EPS (Diluted)-10.70+6.1%
- ROE-50.39%-34.3%
- ROIC-18.04%+10.0%
- Debt/Equity0.75+45.9%
- Interest Coverage-9.08-23.4%
TIL Key Insights
Instil Bio, Inc. (TIL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.5x book value
✗Weaknesses
- ✗Profits declining 13.6% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TIL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TIL Price & Volume
Instil Bio, Inc. (TIL) stock price & volume — 10-year historical chart
Loading chart...
TIL Growth Metrics
Instil Bio, Inc. (TIL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM39.29%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM40.85%
Return on Capital
10 Years-38.57%
5 Years-33.36%
3 Years-30.23%
Last Year-23.29%
TIL Recent Earnings
Instil Bio, Inc. (TIL) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 15, 2026EPS
$0.62
Est $0.62
+0.0%
Revenue
—
Q2 2026
Mar 27, 2026EPS
$1.21
Est $2.31
+47.6%
Revenue
—
Est $2M
Q4 2025
Nov 13, 2025EPS
$2.01
Est $2.00
-0.5%
Revenue
—
Q3 2025
Aug 13, 2025EPS
$3.24
Est $1.72
-88.4%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.62vs $0.62+0.0% | — |
| Q2 2026 | Mar 27, 2026 | $1.21vs $2.31+47.6% | —vs $2M |
| Q4 2025 | Nov 13, 2025 | $2.01vs $2.00-0.5% | — |
| Q3 2025 | Aug 13, 2025 | $3.24vs $1.72-88.4% | — |
Based on last 12 quarters of dataView full earnings history →
TIL Peer Comparison
Instil Bio, Inc. (TIL) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IOVA | 1.46B | 4.08 | -3.74 | 60.6% | -123.9% | -50.17% | 0.07 | |
 ADCT | 133.55M | 1.05 | -0.94 | 14.85% | -173.02% | |||
 FATE | 240.11M | 2.06 | -1.79 | -51.24% | -20.57% | -58.89% | 0.38 | |
 TGTX | 7.58B | 49.52 | 17.88 | 87.32% | 65.95% | 87.36% | 0.40 | |
 CRIS | 81.54M | 0.42 | -0.73 | -13.43% | -299.66% | -138.81% | 0.30 | |
 KYMR | 7.04B | 86.21 | -23.36 | -16.72% | -6.12% | -25.02% | 0.05 | |
 NKTR | 1.16B | 59.38 | -6.10 | -43.89% | -284.18% | -87% | 1.66 | |
 ALNY | 37.74B | 282.85 | 121.39 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare TIL vs Peers
Instil Bio, Inc. (TIL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TIL Income Statement
Instil Bio, Inc. (TIL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 138K | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | -100% | - | - | - | - | - |
Cost of Goods Sold | 20K | 0 | 0 | 5.99M | 0 | 0 | 534K | 24K |
COGS % of Revenue | - | - | - | - | - | - | - | - |
Gross Profit | -20K▲ 0% | 138K▲ 790.0% | 0▼ 100.0% | -5.99M▲ 0% | 0▲ 100.0% | 0▲ 0% | -534K▲ 0% | -24K▲ 0% |
Gross Margin % | - | 100% | - | - | - | - | - | - |
Gross Profit Growth % | - | 790% | -100% | - | 100% | - | - | - |
Operating Expenses | 6.58M | 33.78M | 155.56M | 200.18M | 159.17M | 73.54M | 52.37M | 54.01M |
OpEx % of Revenue | - | 24479.71% | - | - | - | - | - | - |
Selling, General & Admin | 2.56M | 14.38M | 51.31M | 62.23M | 47.55M | 44.21M | 27.22M | 23.46M |
SG&A % of Revenue | - | 10422.46% | - | - | - | - | - | - |
Research & Development | 4.03M | 19.4M | 107.25M | 141.06M | 39.6M | 11.84M | 10M | 20.04M |
R&D % of Revenue | - | 14057.25% | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | -3M | -3.11M | 72.01M | 17.49M | 15.15M | 988K |
Operating Income | -6.58M▲ 0% | -33.64M▼ 410.9% | -155.56M▼ 362.4% | -206.17M▼ 32.5% | -159.17M▲ 22.8% | -73.54M▲ 53.8% | -52.91M▲ 28.1% | -54.04M▲ 0% |
Operating Margin % | - | -24379.71% | - | - | - | - | - | - |
Operating Income Growth % | - | -410.92% | -362.37% | -32.53% | 22.8% | 53.8% | 28.06% | - |
EBITDA | -6.57M | -33.39M | -152.81M | -200.18M | -154.41M | -69.93M | -52.37M | -53.75M |
EBITDA Margin % | - | -24194.2% | - | - | - | - | - | - |
EBITDA Growth % | - | -408.58% | -357.67% | -31% | 22.86% | 54.71% | 25.11% | 29.91% |
D&A (Non-Cash Add-back) | 20K | 256K | 2.75M | 5.99M | 4.76M | 3.61M | 534K | 291K |
EBIT | -6.52M | -33.64M | -155.27M | -223.37M | -151.87M | -66.14M | -52.91M | -45.25M |
Net Interest Income | 68K | 70K | 80K | 1.77M | 3.66M | -2M | -1.97M | -2.13M |
Interest Income | 68K | 70K | 80K | 3.65M | 8.87M | 6.99M | 3.86M | 3.36M |
Interest Expense | 0 | 0 | 0 | 1.88M | 5.21M | 8.99M | 5.83M | 5.49M |
Other Income/Expense | 63K | -3.94M | -1.2M | -19.08M | 3.08M | -594K | -18.46M | 6.66M |
Pretax Income | -6.52M▲ 0% | -37.59M▼ 476.3% | -156.75M▼ 317.0% | -225.25M▼ 43.7% | -156.09M▲ 30.7% | -74.14M▲ 52.5% | -71.37M▲ 3.7% | -47.38M▲ 0% |
Pretax Margin % | - | -27236.96% | - | - | - | - | - | - |
Income Tax | 0 | 151K | 39K | -2.07M | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | -0.4% | -0.02% | 0.92% | 0% | 0% | 0% | 0% |
Net Income | -6.45M▲ 0% | -37.74M▼ 484.7% | -156.79M▼ 315.5% | -223.18M▼ 42.3% | -156.09M▲ 30.1% | -74.14M▲ 52.5% | -71.37M▲ 3.7% | -47.38M▲ 0% |
Net Margin % | - | -27346.38% | - | - | - | - | - | - |
Net Income Growth % | - | -484.72% | -315.48% | -42.34% | 30.06% | 52.5% | 3.73% | 39.29% |
Net Income (Continuing) | -6.52M | -37.74M | -156.79M | -223.18M | -156.09M | -74.14M | -71.37M | -47.38M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.01▲ 0% | -5.89▼ 483.2% | -29.60▼ 402.5% | -34.46▼ 16.4% | -24.00▲ 30.4% | -11.39▲ 52.5% | -10.70▲ 6.1% | -6.99▲ 0% |
EPS Growth % | - | -483.17% | -402.55% | -16.42% | 30.35% | 52.54% | 6.06% | 40.85% |
EPS (Basic) | -1.01 | -5.89 | -29.60 | -34.46 | -24.00 | -11.39 | -10.70 | - |
Diluted Shares Outstanding | 6.41M | 6.41M | 5.3M | 6.48M | 6.5M | 6.51M | 6.67M | 6.78M |
Basic Shares Outstanding | 6.41M | 6.41M | 5.3M | 6.48M | 6.5M | 6.51M | 6.67M | 6.78M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
TIL Balance Sheet
Instil Bio, Inc. (TIL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 9.29M | 246.14M | 464.02M | 269.38M | 160.76M | 124.47M | 191.43M | 188.3M |
Cash & Short-Term Investments | 8.89M | 241.71M | 454.1M | 260.92M | 150.36M | 113.31M | 76.13M | 74.57M |
Cash Only | 8.89M | 241.71M | 37.59M | 43.72M | 9.2M | 8.8M | 6.64M | 5.02M |
Short-Term Investments | 0 | 0 | 416.51M | 217.2M | 141.16M | 104.51M | 69.49M | 69.55M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 848K | 7.97M |
Days Sales Outstanding | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - |
Other Current Assets | 391K | 0 | 0 | 8.46M | 1.5M | 1.83M | 114.45M | 105.76M |
Total Non-Current Assets | 190K | 72.87M | 145.96M | 212.75M | 164.87M | 139.1M | 12.09M | 12.13M |
Property, Plant & Equipment | 190K | 55.34M | 122M | 209.34M | 141.07M | 130.34M | 364K | 172K |
Fixed Asset Turnover | - | 0.00x | - | - | - | - | - | 0.00x |
Goodwill | 0 | 5.72M | 5.72M | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 10.1M | 10.1M | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 23.16M | 0 | 0 | 15.1M |
Other Non-Current Assets | 0 | 1.71M | 8.14M | 3.41M | 639K | 8.76M | 11.73M | 11.95M |
Total Assets | 9.48M▲ 0% | 319.01M▲ 3266.5% | 609.98M▲ 91.2% | 482.13M▼ 21.0% | 325.63M▼ 32.5% | 263.57M▼ 19.1% | 203.52M▼ 22.8% | 200.43M▲ 0% |
Asset Turnover | - | 0.00x | - | - | - | - | - | 0.00x |
Asset Growth % | - | 3266.53% | 91.21% | -20.96% | -32.46% | -19.06% | -22.78% | -82.19% |
Total Current Liabilities | 1.42M | 13.28M | 41.36M | 32.79M | 10.56M | 7.9M | 4.84M | 4.72M |
Accounts Payable | 979K | 3.5M | 5.57M | 2.36M | 1.21M | 659K | 779K | 793K |
Days Payables Outstanding | 17.87K | - | - | 143.82 | - | - | 532.46 | 11.49K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 372K | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 2.6M | 13.65M | 4.22M | 1.22M | 2.07M | 3.69M | 3.93M |
Current Ratio | 6.54x | 18.53x | 11.22x | 8.22x | 15.22x | 15.76x | 39.53x | 39.87x |
Quick Ratio | 6.54x | 18.53x | 11.22x | 8.22x | 15.22x | 15.76x | 39.53x | 39.87x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 13.36M | 13.43M | 85.73M | 89.24M | 86.23M | 84.81M | 85.01M |
Long-Term Debt | 0 | 0 | 0 | 72.35M | 81.43M | 84.19M | 84.81M | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 5.17M | 2.88M | 1.02M | 0 | 6K |
Deferred Tax Liabilities | 0 | 0 | 2.43M | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 13.36M | 11M | 8.21M | 4.94M | 1.03M | 8K | 85.01M |
Total Liabilities | 1.42M | 26.64M | 54.78M | 118.52M | 99.8M | 94.13M | 89.66M | 89.73M |
Total Debt | 0 | 0 | 0 | 79.9M | 86.05M | 86.89M | 85.18M | 0 |
Net Debt | -8.89M | -241.71M | -37.59M | 36.19M | 76.86M | 78.08M | 78.54M | -5.02M |
Debt / Equity | - | - | - | 0.22x | 0.38x | 0.51x | 0.75x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.09x |
Interest Coverage | - | - | - | -118.62x | -29.16x | -7.36x | -9.08x | -8.24x |
Total Equity | 8.06M▲ 0% | 292.37M▲ 3529.2% | 555.2M▲ 89.9% | 363.61M▼ 34.5% | 225.83M▼ 37.9% | 169.44M▼ 25.0% | 113.87M▼ 32.8% | 110.7M▲ 0% |
Equity Growth % | - | 3529.18% | 89.9% | -34.51% | -37.89% | -24.97% | -32.8% | -120.6% |
Book Value per Share | 1.26 | 45.61 | 104.76 | 56.15 | 34.72 | 26.03 | 17.08 | 16.32 |
Total Shareholders' Equity | 8.06M | 292.37M | 555.2M | 363.61M | 225.83M | 169.44M | 113.87M | 110.7M |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Retained Earnings | -7.18M | -44.92M | -201.72M | -424.89M | -580.98M | -655.12M | -726.49M | -730.69M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -283K | -87K | -493K | -348K | -228K | -583K | -532K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TIL Cash Flow Statement
Instil Bio, Inc. (TIL) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -5.29M | -29.62M | -122.14M | -180.16M | -82.03M | -55.7M | -36.62M | -33.76M |
Operating CF Margin % | - | -21460.87% | - | - | - | - | - | - |
Operating CF Growth % | - | -459.53% | -312.41% | -47.51% | 54.47% | 32.1% | 34.25% | 109.3% |
Net Income | -6.52M | -37.74M | -156.79M | -223.18M | -156.09M | -74.14M | -71.37M | -47.38M |
Depreciation & Amortization | 20K | 256K | 2.75M | 5.99M | 4.76M | 3.61M | 534K | 48K |
Stock-Based Compensation | 293K | 1.71M | 26.2M | 30.44M | 18.17M | 17.26M | 8.69M | 4.58M |
Deferred Taxes | 0 | 0 | 710K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 550K | 4.68M | 636K | 16.15M | 60.15M | 10.18M | 26.09M | 11.87M |
Working Capital Changes | 366K | 1.48M | 4.36M | -9.57M | -9.02M | -12.61M | -560K | -2.88M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | -3.4M | -608K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 309K | -1.05M | 3.86M | -1.81M | -1.13M | -556K | 116K | 509K |
Cash from Investing | -760K | -51.12M | -474.4M | 114.54M | 41.13M | 53.97M | 25.48M | 15.55M |
Capital Expenditures | -210K | -50.82M | -57.83M | -84.59M | -20.66M | -10M | -10M | -10M |
CapEx % of Revenue | - | 36823.19% | - | - | - | - | - | - |
Acquisitions | 0 | -306K | 0 | 1.17M | 0 | 0 | 432K | 14K |
Investments | - | - | - | - | - | - | - | - |
Other Investing | -550K | 0 | 0 | -1.17M | 1.56M | 866K | 0 | 13K |
Cash from Financing | 14.95M | 313.05M | 393.16M | 71.89M | 8.08M | 1.75M | 7.29M | 7.06M |
Debt Issued (Net) | 0 | 0 | 0 | 70.34M | 8.08M | 2.76M | 6.61M | 6.61M |
Equity Issued (Net) | 14.95M | 312.62M | 391.48M | 1.55M | 0 | 0 | 853K | -6.23M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 430K | 1.69M | 0 | 0 | -1.01M | -172K | 6.68M |
Net Change in Cash | 8.89M▲ 0% | 232.87M▲ 2518.0% | -203.67M▼ 187.5% | 5.63M▲ 102.8% | -33.02M▼ 686.9% | -61K▲ 99.8% | -3.83M▼ 6180.3% | -11.18M▲ 0% |
Free Cash Flow | -6.05M▲ 0% | -80.43M▼ 1228.8% | -179.97M▼ 123.8% | -264.75M▼ 47.1% | -102.69M▲ 61.2% | -65.7M▲ 36.0% | -36.62M▲ 44.3% | -33.76M▲ 0% |
FCF Margin % | - | -58284.06% | - | - | - | - | - | - |
FCF Growth % | - | -1228.8% | -123.75% | -47.11% | 61.21% | 36.03% | 44.26% | 25.8% |
FCF per Share | -0.94 | -12.55 | -33.96 | -40.88 | -15.79 | -10.09 | -5.49 | -4.98 |
FCF Conversion (FCF/Net Income) | 0.82x | 0.78x | 0.78x | 0.81x | 0.53x | 0.75x | 0.51x | 0.71x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 8M | 0 | 1.39M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TIL Key Ratios
Instil Bio, Inc. (TIL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -25.12% | -37% | -48.58% | -52.96% | -37.51% | -50.39% | -39.76% |
| Return on Invested Capital (ROIC) | -101.31% | -41.06% | -33.71% | -33.99% | -20.05% | -18.04% | -22.95% |
| Gross Margin | 100% | - | - | - | - | - | - |
| Net Margin | -27346.38% | - | - | - | - | - | - |
| Debt / Equity | - | - | 0.22x | 0.38x | 0.51x | 0.75x | 0.00x |
| Interest Coverage | - | - | -118.62x | -29.16x | -7.36x | -9.08x | -8.24x |
| FCF Conversion | 0.78x | 0.78x | 0.81x | 0.53x | 0.75x | 0.51x | 0.71x |
| Revenue Growth | - | -100% | - | - | - | - | - |
Related:TIL Dividend History·TIL Revenue History·TIL Price History·TIL P/E History·TIL Financial Ratios·TIL Institutional Holders
TIL SEC Filings & Documents
Instil Bio, Inc. (TIL) SEC filings — annual & quarterly reports (10-K, 10-Q)
TIL Frequently Asked Questions
Instil Bio, Inc. (TIL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Instil Bio, Inc. (TIL) grew revenue by 0.0% over the past year. Growth has been modest.
Instil Bio, Inc. (TIL) reported a net loss of $47.4M for fiscal year 2025.
Dividend & Returns
Instil Bio, Inc. (TIL) has a return on equity (ROE) of -50.4%. Negative ROE indicates the company is unprofitable.
Instil Bio, Inc. (TIL) had negative free cash flow of $33.8M in fiscal year 2025, likely due to heavy capital investments.